SS
AGIO icon

Sunbelt Securities’s Agios Pharmaceuticals AGIO Stock Holding History

Sunbelt Securities’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-225
Closed -$9.7K – 1849
2024
Q2 		$9.7K Buy
+225
New +$8.12K ﹤0.01% 1270

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Sunbelt Securities's AGIO Position: Q3 2024 in Review

Sunbelt Securities sold out of Agios Pharmaceuticals (AGIO) in Q3 2024, closing a stake of 225 shares — an estimated $9.7K sold.

Sunbelt Securities first reported a position in AGIO in Q2 2024 and held it in 1 quarter. The position peaked at $9.7K in Q2 2024. 207 funds tracked by Wall St. Rank hold AGIO as of Q3 2024.

  • Sunbelt Securities reported no remaining Agios Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Sunbelt Securities sold 225 Agios Pharmaceuticals shares in Q3 2024, an estimated $9.7K.
  • Sunbelt Securities first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Sunbelt Securities's Agios Pharmaceuticals position peaked at $9.7K in Q2 2024.
  • 207 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2024.

Based on Sunbelt Securities's 13F filing for Q3 2024, filed 18 Nov 2024.